Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST
Handelsman et al. • 2024 • WCIRDC
© 2024 Corcept Therapeutics, Incorporated
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
Badiu et al. • 2024 • AACE MENA 2024 Congress
Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Gilis-Januszewska et al. • 2024 • AACE MENA 2024 Congress
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
2024 • AACE 2024